@StickyRice:Novavax's COVID-19 shot gets approval for use in teenagers in South KoreaNovavax (NASDAQ:NVAX) $Novavax(NVAX)$on Friday said its protein-based COVID-19 vaccine had received an expanded approval in South Korea for use in teenagers aged 12 to 17 years.The U.S. company's partner, SK bioscience, got a post approval change application nod from the Korean Ministry of Food and Drug Safety for the COVID shot, Nuvaxovid, NVAX said in a statement."Today's approval in South Korea is an important step in ensuring broad global access to a protein-based vaccine option," said NVAX CEO Stanley Erck.Nuvaxovid had already been given approval for use in teenagers aged 12 through 17 years in India, the European Union, Australia, Thailand and